Kardigan (NASDAQ:KARD) shares are sharply lower in Wednesday's session, tumbling over 10% to trade near a 52-week low around $14.72, reversing a modest gain from earlier in the week. The sell-off comes despite recent commentary highlighting the company's decision to invest in and deliver …
Labcorp Holdings (NYSE:LH) shares are declining in Wednesday's session after the Centers for Medicare and Medicaid Services released preliminary 2027-2029 Clinical Laboratory Fee Schedule payment rates that the company warns would impose steep annual Medicare payment cuts on lab services, a change it argues …
AstraZeneca (NYSE:AZN) shares are declining sharply in Wednesday's session, underperforming the broader healthcare sector, which has been comparatively resilient amid a mixed macro backdrop of oil price swings andEquitymarketVolatilitytied to AI trade rotation and looming U.S.-China trade talks. The drop comes despite routine positive …
BridgeBio Pharma (NASDAQ:BBIO) shares are extending a multi-week slide in Wednesday's session, falling further despite the company announcing new peer-reviewed real-world data showing its lead drug acoramidis, marketed as Attruby, reduced a composite of clinical worsening events by 34% versus rival tafamidis in patients …
Cullinan Therapeutics (NASDAQ:CGEM) shares are sliding sharply in Wednesday's session, giving back a significant portion of recent gains driven by updated Phase 3 REZILIENT3 data on zipalertinib, partnered with Taiho Pharmaceutical, in EGFR exon20ins non-small cell lung cancer. The underlying data itself showed a …
Hims & Hers Health (NYSE:HIMS) shares are declining sharply in Wednesday's session, extending a multi-week slide as legal and regulatory overhang deepens. A securities fraud class action was filed on September 21, with a lead plaintiff deadline of November 2, compounding the FTC's July …
Ascendis Pharma (NASDAQ:ASND) shares are sliding in Wednesday's session as investors digest the company's decision to terminate its collaboration agreement with Novo Nordisk (NYSE:NVO), reclaiming full rights to its TransCon technology-based metabolic and cardiovascular pipeline, including once-monthly TransCon Semaglutide. While the move gives Ascendis …
Apnimed (NASDAQ:APMD) shares are sliding sharply in Wednesday's session, extending a multi-day decline of over 25% from last week's levels above $29. Heavy insider and institutional selling pressure appears to be weighing on the stock following its recent addition to the S&P Total Market …
Ardent Health (NYSE:ARDT) shares declined in Wednesday's session as a research firm initiated coverage with a cautious Market Perform rating and an $11 price target, signaling limited near-term upside from the current trading price. The initiation contrasts with more bullish stances from other analysts, …
Artelo Biosciences (NASDAQ:ARTL) shares are soaring after the company filed a provisional patent application covering its drug candidate ART27.13 for the treatment of obesity, both as a standalone therapy and in combination with GLP-1 receptor agonists such as semaglutide, the active ingredient in Ozempic …